GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cepheid (NAS:CPHD) » Definitions » Beneish M-Score

Cepheid (Cepheid) Beneish M-Score : 0.00 (As of May. 12, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Cepheid Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Cepheid's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Cepheid was 0.00. The lowest was 0.00. And the median was 0.00.


Cepheid Beneish M-Score Historical Data

The historical data trend for Cepheid's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cepheid Beneish M-Score Chart

Cepheid Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.80 -2.34 -2.63 -2.89 -2.99

Cepheid Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.00 -2.99 -2.90 -3.21 -2.74

Competitive Comparison of Cepheid's Beneish M-Score

For the Diagnostics & Research subindustry, Cepheid's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cepheid's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cepheid's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cepheid's Beneish M-Score falls into.



Cepheid Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cepheid for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.19+0.528 * 1.0222+0.404 * 0.4767+0.892 * 1.1399+0.115 * 1.0604
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8552+4.679 * -0.085635-0.327 * 0.9831
=-2.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep16) TTM:Last Year (Sep15) TTM:
Total Receivables was $81.9 Mil.
Revenue was 158.488 + 146.001 + 144.78 + 146.999 = $596.3 Mil.
Gross Profit was 75.098 + 72.766 + 72.185 + 75.394 = $295.4 Mil.
Total Current Assets was $629.9 Mil.
Total Assets was $847.4 Mil.
Property, Plant and Equipment(Net PPE) was $151.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $36.9 Mil.
Selling, General, & Admin. Expense(SGA) was $191.9 Mil.
Total Current Liabilities was $146.5 Mil.
Long-Term Debt & Capital Lease Obligation was $289.8 Mil.
Net Income was -10.907 + -10.232 + -6.601 + -9.805 = $-37.5 Mil.
Non Operating Income was -1.012 + 0.298 + -0.528 + -0.796 = $-2.0 Mil.
Cash Flow from Operations was 0.745 + 33.851 + -9.113 + 11.573 = $37.1 Mil.
Total Receivables was $60.4 Mil.
Revenue was 126.465 + 132.475 + 132.637 + 131.522 = $523.1 Mil.
Gross Profit was 58.784 + 63.098 + 71.436 + 71.637 = $265.0 Mil.
Total Current Assets was $562.4 Mil.
Total Assets was $821.5 Mil.
Property, Plant and Equipment(Net PPE) was $124.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $32.7 Mil.
Selling, General, & Admin. Expense(SGA) was $196.8 Mil.
Total Current Liabilities was $144.8 Mil.
Long-Term Debt & Capital Lease Obligation was $285.4 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(81.91 / 596.268) / (60.383 / 523.099)
=0.137371 / 0.115433
=1.19

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(264.955 / 523.099) / (295.443 / 596.268)
=0.50651 / 0.495487
=1.0222

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (629.861 + 151.227) / 847.357) / (1 - (562.365 + 124.366) / 821.495)
=0.078207 / 0.164047
=0.4767

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=596.268 / 523.099
=1.1399

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(32.675 / (32.675 + 124.366)) / (36.918 / (36.918 + 151.227))
=0.208067 / 0.196221
=1.0604

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(191.855 / 596.268) / (196.821 / 523.099)
=0.32176 / 0.37626
=0.8552

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((289.758 + 146.475) / 847.357) / ((285.406 + 144.77) / 821.495)
=0.514816 / 0.52365
=0.9831

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-37.545 - -2.038 - 37.056) / 847.357
=-0.085635

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cepheid has a M-score of -2.74 suggests that the company is unlikely to be a manipulator.


Cepheid Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Cepheid's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cepheid (Cepheid) Business Description

Traded in Other Exchanges
N/A
Address
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
Executives
Thomas D Brown director 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK, LAKE MARY FL 32746-6232
Hollings Renton director
John L Bishop director, officer: Chairman of the Board and CEO
Marc Haugen officer: EVP, Global Ops & Engineering C/O CEPHEID, 904 CARIBBEAN DRIVE, SUNNYVALE CA 94089
Ilan Daskal officer: EVP, Chief Financial Officer 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew Miller officer: EVP, CFO 111 MCINNIS PARKWAY, SAN RAFAEL CA 94903
Jim Post officer: EVP, NA Commercial Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453

Cepheid (Cepheid) Headlines

From GuruFocus

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 05-04-2010

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2010

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2009

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-08-2011

Baron Funds Comments on Cepheid

By Holly LaFon Holly LaFon 02-08-2016

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-28-2011

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 08-04-2010

Mario Gabelli Comments on Cepheid

By Holly LaFon Holly LaFon 01-31-2017

CEPHEID Reports Operating Results (10-Q)

By gurufocus 05-07-2009

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-15-2011